AR100444A1 - Uso de palmitoiletanolamida en combinación de opioides - Google Patents
Uso de palmitoiletanolamida en combinación de opioidesInfo
- Publication number
- AR100444A1 AR100444A1 ARP150101502A ARP150101502A AR100444A1 AR 100444 A1 AR100444 A1 AR 100444A1 AR P150101502 A ARP150101502 A AR P150101502A AR P150101502 A ARP150101502 A AR P150101502A AR 100444 A1 AR100444 A1 AR 100444A1
- Authority
- AR
- Argentina
- Prior art keywords
- palmitoylethanolamide
- opioid
- combination
- opioid combination
- micronized form
- Prior art date
Links
- 229950007031 palmidrol Drugs 0.000 title abstract 4
- HXYVTAGFYLMHSO-UHFFFAOYSA-N palmitoyl ethanolamide Chemical compound CCCCCCCCCCCCCCCC(=O)NCCO HXYVTAGFYLMHSO-UHFFFAOYSA-N 0.000 title abstract 4
- 241001465754 Metazoa Species 0.000 abstract 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 abstract 2
- 230000000202 analgesic effect Effects 0.000 abstract 1
- 229960005181 morphine Drugs 0.000 abstract 1
- 229940005483 opioid analgesics Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Dispersion Chemistry (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI20140876 | 2014-05-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR100444A1 true AR100444A1 (es) | 2016-10-05 |
Family
ID=51179022
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150101502A AR100444A1 (es) | 2014-05-14 | 2015-05-14 | Uso de palmitoiletanolamida en combinación de opioides |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9801836B2 (enExample) |
| EP (1) | EP2944309B1 (enExample) |
| JP (1) | JP6563685B2 (enExample) |
| KR (1) | KR102507891B1 (enExample) |
| CN (1) | CN105079811B (enExample) |
| AR (1) | AR100444A1 (enExample) |
| AU (1) | AU2015202575B9 (enExample) |
| BR (1) | BR102015011079A2 (enExample) |
| CA (1) | CA2891049C (enExample) |
| CY (1) | CY1121773T1 (enExample) |
| DK (1) | DK2944309T3 (enExample) |
| ES (1) | ES2731729T3 (enExample) |
| HU (1) | HUE044915T2 (enExample) |
| PL (1) | PL2944309T3 (enExample) |
| PT (1) | PT2944309T (enExample) |
| SM (1) | SMT201900345T1 (enExample) |
| TR (1) | TR201908936T4 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL322263A (en) * | 2015-05-21 | 2025-09-01 | Scisparc Ltd | Combinations of opioids and acetylamines |
| PH12018000077B1 (en) | 2017-07-05 | 2021-07-09 | Frimline Private Ltd | A pharmaceutical composition for neuropathic pain |
| PH12018000227A1 (en) | 2017-09-05 | 2019-03-11 | Frimline Private Ltd | A pharmaceutical composition for improving or preventing progression of chronic kidney disease |
| WO2020141546A1 (en) * | 2019-01-02 | 2020-07-09 | Celagenex Research (India) Pvt. Ltd. | Synergistic nutritional compositions for pain management |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1271266B (it) | 1994-12-14 | 1997-05-27 | Valle Francesco Della | Impiego terapeutico di ammidi di acidi mono e bicarbossilici con amminoalcoli,selettivamente attive sul recettore periferico dei cannabinoidi |
| US6548550B1 (en) | 1999-08-06 | 2003-04-15 | Innovet Italia S.R.L. | Pharmaceutical compositions containing N-palmitoylethanolamide and use thereof in the veterinary field |
| ES2312643T5 (es) * | 2001-07-18 | 2011-10-18 | Unilever N.V. | Composiciones para el tratamiento del cabello y/o del cuero cabelludo. |
| US20050245557A1 (en) * | 2003-10-15 | 2005-11-03 | Pain Therapeutics, Inc. | Methods and materials useful for the treatment of arthritic conditions, inflammation associated with a chronic condition or chronic pain |
| JP2012522004A (ja) * | 2009-03-27 | 2012-09-20 | アボット・ラボラトリーズ | カンナビノイド受容体リガンドである化合物 |
| PL2796129T3 (pl) * | 2009-09-07 | 2015-11-30 | Epitech Group S P A | Kompozycja zawierająca palmitoiloetanoloamid poddany ultramikronizacji |
-
2015
- 2015-05-04 DK DK15166284.8T patent/DK2944309T3/da active
- 2015-05-04 HU HUE15166284 patent/HUE044915T2/hu unknown
- 2015-05-04 EP EP15166284.8A patent/EP2944309B1/en active Active
- 2015-05-04 SM SM20190345T patent/SMT201900345T1/it unknown
- 2015-05-04 TR TR2019/08936T patent/TR201908936T4/tr unknown
- 2015-05-04 PL PL15166284T patent/PL2944309T3/pl unknown
- 2015-05-04 PT PT15166284T patent/PT2944309T/pt unknown
- 2015-05-04 ES ES15166284T patent/ES2731729T3/es active Active
- 2015-05-12 CA CA2891049A patent/CA2891049C/en active Active
- 2015-05-13 KR KR1020150066492A patent/KR102507891B1/ko active Active
- 2015-05-13 CN CN201510243856.6A patent/CN105079811B/zh active Active
- 2015-05-13 AU AU2015202575A patent/AU2015202575B9/en active Active
- 2015-05-13 JP JP2015098334A patent/JP6563685B2/ja active Active
- 2015-05-13 US US14/711,112 patent/US9801836B2/en active Active
- 2015-05-14 BR BR102015011079A patent/BR102015011079A2/pt not_active IP Right Cessation
- 2015-05-14 AR ARP150101502A patent/AR100444A1/es unknown
-
2019
- 2019-05-29 CY CY20191100565T patent/CY1121773T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR102507891B1 (ko) | 2023-03-08 |
| KR20150130931A (ko) | 2015-11-24 |
| CA2891049C (en) | 2023-02-21 |
| CA2891049A1 (en) | 2015-11-14 |
| DK2944309T3 (da) | 2019-06-03 |
| BR102015011079A2 (pt) | 2016-03-29 |
| PL2944309T3 (pl) | 2019-09-30 |
| CN105079811B (zh) | 2020-06-23 |
| CN105079811A (zh) | 2015-11-25 |
| PT2944309T (pt) | 2019-06-05 |
| AU2015202575A1 (en) | 2015-12-03 |
| JP6563685B2 (ja) | 2019-08-21 |
| AU2015202575B9 (en) | 2020-03-26 |
| US20150328173A1 (en) | 2015-11-19 |
| HUE044915T2 (hu) | 2019-11-28 |
| SMT201900345T1 (it) | 2019-07-11 |
| US9801836B2 (en) | 2017-10-31 |
| TR201908936T4 (tr) | 2019-07-22 |
| AU2015202575B2 (en) | 2020-03-05 |
| CY1121773T1 (el) | 2020-07-31 |
| ES2731729T3 (es) | 2019-11-18 |
| EP2944309A1 (en) | 2015-11-18 |
| JP2015221794A (ja) | 2015-12-10 |
| EP2944309B1 (en) | 2019-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NI201900041A (es) | 1, 2, 4-triazolonas 2, 4, 5-trisustituidas | |
| BR112016020618A8 (pt) | oligômero antissentido, composição farmacêutica, e, uso de um oligômero antissentido | |
| SV2017005461A (es) | Benzamidas sustituidas con 1,3-tiazol-2-ilo | |
| CL2016002735A1 (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer | |
| NI201600071A (es) | Compuestos de inhibidor de autotaxina | |
| SV2016005257A (es) | Benzimidazol-2-aminas como inhibidores de midh1 | |
| CL2015002736A1 (es) | Composición farmacéutica de clorhidrato de s-ketamina. | |
| BR112016012781A2 (pt) | Novos métodos | |
| UY37460A (es) | 1,2,4-triazolonas con anelación en 4 y 5 | |
| ECSP17018120A (es) | Triazolopirazinonas como inhibidores de pde1 | |
| MX377877B (es) | Composiciones de solución sólida y su uso en el tratamiento del dolor intenso. | |
| MX2016011744A (es) | Soluciones de buprenorfina de liberacion sostenida. | |
| MX2018015734A (es) | 1h-pirazolo[4,3-b]piridinas como inhibidores de pde1. | |
| MX2017006113A (es) | Nuevos profarmacos polimericos de la hormona del crecimiento humana (hgh). | |
| CL2017003066A1 (es) | Composiciones de carbonato de calcio amorfo para administración mediante inhalación, sublingual o bucal | |
| BR112017012504A2 (pt) | derivados de piperidina como inibidores de hdac1/2 | |
| NI201600070A (es) | Inhibidores tetracíclicos de autotaxina | |
| MX2017005484A (es) | Compuestos antagonistas del receptor de dopamina d3. | |
| MX389333B (es) | Formulacion de buprenorfina inyectable. | |
| DOP2016000170A (es) | Compuestos derivados de hidroxiformamida y usos del mismo | |
| CL2019001550A1 (es) | Fenytoina tópica para uso en el tratamiento del dolor neuropático periférico. | |
| CL2016001570A1 (es) | Uso de un antagonista de receptores de opioides con actividad %u039a y vortioxetina para el tratamiento de trastorno depresivo con características melancólicas | |
| AR100444A1 (es) | Uso de palmitoiletanolamida en combinación de opioides | |
| MX2015009277A (es) | Formas de dosificacion y usos terapauticos de l-4-cloro quinurenina. | |
| BR112016009749A8 (pt) | hidromorfona e naloxona para tratamento de dor e síndrome de disfunção intestinal opioide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |